Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a report issued on Monday. They presently have a GBX 970 ($12.62) price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 13.52% from the stock’s previous close.

CLIN has been the subject of a number of other research reports. Peel Hunt lifted their target price on Clinigen Group PLC from GBX 1,000 ($13.01) to GBX 1,015 ($13.20) and gave the stock a “buy” rating in a report on Friday, February 24th. N+1 Singer reaffirmed a “buy” rating and issued a GBX 895 ($11.64) price objective on shares of Clinigen Group PLC in a report on Wednesday, March 15th. Finally, Numis Securities Ltd reaffirmed a “buy” rating and issued a GBX 933 ($12.14) price objective on shares of Clinigen Group PLC in a report on Friday, March 10th.

Shares of Clinigen Group PLC (LON:CLIN) traded down 0.12% on Monday, reaching GBX 854.50. The company’s stock had a trading volume of 331,634 shares. The company’s market cap is GBX 981.82 million. Clinigen Group PLC has a 52-week low of GBX 492.75 and a 52-week high of GBX 890.00. The stock has a 50-day moving average of GBX 834.65 and a 200 day moving average of GBX 792.97.

ILLEGAL ACTIVITY NOTICE: “Stifel Nicolaus Reiterates “Buy” Rating for Clinigen Group PLC (CLIN)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at

About Clinigen Group PLC

12 Month Chart for LON:CLIN

Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with's FREE daily email newsletter.